On 9 November 2026, Denglin Tech-P (09917.HK) set its final offer price at HK$231.00 per share, the bottom of the range. The Hong Kong public offer was 2.11 times subscribed and the international offering 1.34 times, with net proceeds of HK$1,312.4 million. The H shares list on 10 November.
YIDU TECH said its affiliate won the bid for the digital platform of Tongji Hospital's Sino-French New Town campus expansion project at about RMB9.161 million.
LONGCHEER said chairman Du Junhong completed his H-share purchase plan, buying 650,000 shares for about RMB10.35 million to lift votes to 35.46%.
CHANGMAO BIO said its unit replaced an RMB93 million project loan balance with a 10-year bank facility priced at LPR minus 0.5%, with the company as guarantor.
DENGLIN TECH-P closed its grey market session at HK$221.20 on November 9, down 4.24% from its HK$231 offer price, with listing set for November 10.
CHINASOFT INT'L said it has won a billion-level enterprise data modernization project from a leading Southeast Asian bank, to be built on Huawei DWS.
On November 9, the HSI fell 0.13% and the HSTECH 0.92%. MICOT PHARMA-B rose 29.82% on Phase III completion, as southbound funds bought HK$1.856 billion net.
On 9 November 2026, CITIC (00267.HK) said its subsidiary Nangang's controlling shareholder merger is still pending deregistration and the share transfer.
On November 9, the HSI fell 0.13% and the HSTECH 0.92% as early gains faded. UBTECH ROBOTICS rose 8.99% on a telecom pact; 11 of 20 AI concept stocks declined.
On November 9, 2026, Hong Kong ETFs advanced across regional markets while technology themes eased. ChinaAMC MSCI India ETF (03404.HK) rose 5.99% to lead, with iShares Core S&P BSE SENSEX India ETF (02836.HK) up 4.81% and two Japan ETFs up more than 3.4%; the largest decliner, Guotai Haitong Global Future Tech ETF (03585.HK), fell just 3.83%, while Southbound biotech and dividend products edged higher.
On 9 November 2026, SHENZHEN INVEST (00604.HK) put a Shenzhen warehouse up for public listing at a reserve price of RMB 492,915,251.52, deposit 10.4%.
On 9 November 2026, SIMCERE PHARMA (02096.HK) said Germany cleared its TL1A/IL-23p19 bispecific antibody SIM0709 for a phase I trial in healthy volunteers.
On November 9, Hong Kong stocks weakened, the Hang Seng Index down 0.13% on turnover of 173.7 billion HKD and southbound net buying of 1.856 billion HKD.
On November 9, 2026, RELYEZ ENERGY topped the gainers with a rise of 59.00%; LDROBOT, METIS TECHBIO-P and IMPACT THERAP-B will see lock-up expiries this week, while TOPNC, UISEE TECH and TENNOR THERAP-B will see lock-up expiries next week.
HOSIN closed IPO subscription on November 9 at HK$72.29-82.90 for a November 12 listing; margin financing hit HK$220 million, 1.79 times the public offer.
After being added to the Stock Connect list on 7 September, southbound holdings in SENASIC (06675.HK) rose from 53,000 shares on 9 September to 2,295,800 shares on 6 November, with the ratio to issued H shares rising from below 0.01% to 0.60%. The company published a circular on 4 November for an extraordinary general meeting on 24 November to consider five resolutions, including general mandates to issue shares and to repurchase H shares.
